Search
News & Events
The Kids researchers named as finalists in 2023 Premier’s Science AwardsFive The Kids Research Institute Australia researchers working across diverse and highly impactful areas of child health research have been named as finalists for the 2023 Premier’s Science Awards.
News & Events
Allied Health award for respiratory researcher Dr Pamela LairdCongratulations to respiratory health clinician-researcher Dr Pamela Laird, who has won Allied Health Researcher of the Year at the WA Excellence in Allied Health Awards.
News & Events
Research to see if AI can speed up therapy for people with antibiotic-resistant bacterial infectionsResearchers from the Wal-yan Respiratory Research Centre are aiming to combine artificial intelligence with natural, infection-fighting viruses to help save lives from an increasingly common medical emergency found in hospitals.
News & Events
How summer bushfires can impact your family’s healthBushfires can have a considerable impact on our health, with some symptoms lasting long after the flames are extinguished. And our children are amongst the most vulnerable.
News & Events
International Day of Education: AI and Education at The Kids Research InstituteToday, 24 January 2025, is International Day of Education, a global celebration of the power of learning to transform lives. This year’s theme, “AI and Education: Preserving Human Agency in an Automated World”, underscores the critical role of education in preparing kids for a future increasingly shaped by AI.
Research
Monitoring disease progression in childhood bronchiectasisBronchiectasis (not related to cystic fibrosis) is a chronic lung disease caused by a range of etiologies but characterized by abnormal airway dilatation, recurrent respiratory symptoms, impaired quality of life and reduced life expectancy.
Research
The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trialStructural lung disease and neutrophil-dominated airway inflammation is present from 3 months of age in children diagnosed with cystic fibrosis after newborn screening. We hypothesised that azithromycin, given three times weekly to infants with cystic fibrosis from diagnosis until age 36 months, would reduce the extent of structural lung disease as captured on chest CT scans.
Research
BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosisCystic fibrosis (CF) is a rare, inherited, life-limiting condition predominantly affecting the lungs, for which there is no cure. The disease is characterized by recurrent pulmonary exacerbations (PEx), which are thought to drive progressive lung damage. Management of these episodes is complex and generally involves multiple interventions targeting different aspects of disease. The emergence of innovative trials and use of Bayesian statistical methods has created renewed opportunities for studying heterogeneous populations in rare diseases.
Research
Learning to make a difference for chILD: Value creation through network collaboration and team scienceAddressing the recognized challenges and inequalities in providing high quality healthcare for rare diseases such as children's interstitial lung disease (chILD) requires collaboration across institutional, geographical, discipline, and system boundaries. The Children's Interstitial Lung Disease Respiratory Network of Australia and New Zealand (chILDRANZ) is an example of a clinical network that brings together multidisciplinary health professionals for collaboration, peer learning, and advocacy with the goal of improving the diagnosis and management of this group of rare and ultra-rare conditions.
Research
Development and validation of a miniaturized bacteriophage host range screening assay against antibiotic resistant Pseudomonas aeruginosaAntimicrobial resistance is a current global health crisis, and the increasing emergence of multidrug resistant infections has led to the resurgent interest in bacteriophages as an alternative treatment.